Pigmented Villonodular Synovitis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Pigmented Villonodular Synovitis – Pipeline Review, H2 2019’, provides an overview of the Pigmented Villonodular Synovitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Pigmented Villonodular Synovitis

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pigmented Villonodular Synovitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Bristol-Myers Squibb Co

F. Hoffmann-La Roche Ltd

Nippon Chemiphar Co Ltd

Novartis AG

Pfizer Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pigmented Villonodular Synovitis - Overview

Pigmented Villonodular Synovitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pigmented Villonodular Synovitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

F. Hoffmann-La Roche Ltd

Novartis AG

Pfizer Inc

Plexxikon Inc

Pigmented Villonodular Synovitis - Drug Profiles

cabiralizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emactuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lacnotuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-0360324 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexidartinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-73086 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pigmented Villonodular Synovitis - Product Development Milestones

Featured News & Press Releases

Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis

May 14, 2014: Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting

May 14, 2014: Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extension Data in Patients with Pigmented Villonodular Synovitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Pigmented Villonodular Synovitis, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pigmented Villonodular Synovitis – Pipeline by Bristol-Myers Squibb Co, H2 2019

Pigmented Villonodular Synovitis – Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Pigmented Villonodular Synovitis – Pipeline by Nippon Chemiphar Co Ltd, H2 2019

Pigmented Villonodular Synovitis – Pipeline by Novartis AG, H2 2019

Pigmented Villonodular Synovitis – Pipeline by Pfizer Inc, H2 2019

Pigmented Villonodular Synovitis – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports